The global drive for universal health coverage (UHC) provides important opportunities for strengthening TB control by emphasizing the need for more sustainable and effective funding models and the promotion of policies designed to improve universal access to high-quality diagnosis, care, and treatment.  In many countries, efforts to achieve UHC have taken the form of

In 2010, the World Health Organisation (WHO) released Guidance on Ethics of Tuberculosis Prevention, Care and Control.  This guidance is meant to address all dilemmas related to the rights of TB patients, the community, TB programmes, and healthcare workers in the management of TB patients. The purpose of this tool is for programmes to assess

TB disease occurs most often within the context of economic and social vulnerabilities, and patients receiving TB treatment frequently experience other psychological, social and economic problems that may interfere with their ability to complete treatment. An episode of TB may further exacerbate poverty or reduce a patient or family’s economic and social well-being, and even

A new technology entitled GeneXpert was deemed a ‘game-changer’ in the world of TB diagnostics. To reduce the burden and mortality of TB, it is imperative to not only have advanced technologies to detect TB bacteria, but to also have experts that know how to use the new technology. In 2016, USAID TB CARE II

A training curriculum for an Ethics of Tuberculosis Prevention, Care, and Control training course has been developed. The training curriculum includes a facilitator-led training guide along with presentations and activities for the interactive 2-day course which is intended to introduce the concept of ethics in tuberculosis prevention, care, and control and to sensitize and educate delegates on

In 2014, approximately 480,000 people developed MDR-TB.  3.3% of new cases and 20% of previously treated patients develop MDR-TB.  It was estimated that only 41% of cases were notified that they had MDR-TB in 2014.  In low and middle-income countries, access to quality TB services is often limited.  Since the beginning of TB CARE II

In April 2014, TB CARE II, in partnership with the Tajikistan Ministry of Health and Social Protection, established the Macheton National TB Hospital in Tajikistan as an infection control demonstration site. The purpose of this site is to document the magnitude of TB burden caused by poor infection control, establish more effective infection control